EGFR and non-small cell lung carcinoma: Recently, there have been multiple promising breakthroughs in the first-line therapy of advanced EGFR-mutated NSCLC cases including those derived from the FLAURA2 study [12], MARIPOSA study [13], LASER301 study [14], and IBIO-103 study [15].